Press Releases

BioAlliance Pharma submits application for orphan medicinal product designation for clonidine Lauriad™ in Europe and the United States

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, today announced the submission to the European (EMA) and American (FDA) Drug Agencies of an application for orphan medicinal product designation for clonidine Lauriad™, in the prevention of radiotherapy-induced oral mucositis in patients with head and neck cancer. Clonidine Lauriad™, presently…read more →

BioAlliance Pharma strengthens its proprietary technologies with the grant of its Lauriad™ patents in Asia and with the transfer of Setofilm® back to APR Applied Pharma Research SA, the owner of the technology

BioAlliance Pharma SA (Euronext Paris –BIO), a company dedicated to the supportive care and treatment of cancer patients, today announced the grant of patents protecting its delivery technology Lauriad™ in China and Japan. This delivery technology specifically covers its advanced Specialty products: Loramyc® in the treatment of oropharyngeal candidiasis and Sitavir® in herpes labialis. “After Europe and the US, these…read more →

BioAlliance Pharma filed an appeal to the French Supreme Court contesting a preliminary procedural decision on jurisdiction in the arbitration against SpePharm and SpeBio

The proceedings to the arbitral tribunal are still at a preliminary stage concerning the scope of its jurisdiction. This tribunal will have to rule on the relief sought by BioAlliance Pharma and the counterclaims of SpePharm and SpeBio. BioAlliance Pharma announces today that it has filed an appeal to the French Supreme Court on a procedural matter in this arbitral…read more →

A new Chief Executive Officer to strengthen BioAlliance Pharma’s growth

BioAlliance Pharma SA (Euronext Paris –BIO), a company dedicated to the supportive care and treatment of cancer patients, today announced the appointment of Judith Greciet as Chief Executive Officer, succeeding to Dominique Costantini, co-foundator and Chief Executive Officer, to be effective after the General Assembly Meeting of June 29, 2011. Judith Greciet, PharmD, serves as Chief Operating Officer for BioAlliance…read more →

Combined Ordinary and Extraordinary General Meeting on June 29th 2011

Procedures for obtaining preparatory documents BioAlliance Pharma’s shareholders are invited to attend the Combined Ordinary and Extraordinary General Meeting to be held at 2.00 pm on June 29th 2011 at the company’s head office (49 Boulevard du Général Martial Valin, F-75015 Paris, France). The official notice of the Meeting will be published in the French Republic’s Bulletin des Annonces Légales…read more →

Board evolution at BioAlliance Pharma To support its growth strategy

BioAlliance Pharma’s (Euronext Paris –BIO) Board has approved the draft resolutions on Board changes, to be voted at the General Assembly Meeting on June 29, 2011. Following Mr. André Ulmann and Mr. Gilles Marrache expressed wishes not to pursue their board mandate due to personal constraints, the Board thanks them for their commitment and contribution to its work and will…read more →

BioAlliance Pharma announces that Therabel launches Loramyc®

in Germany with the support of Hikma BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to specialty and orphan pharma products in oncology and supportive care, today announced that Loramyc® has been launched in Germany by its European partner Therabel. Therabel has created a fully dedicated team and has also entered into a co-promotion agreement with Hikma Pharma…read more →

Q1 2011: achievement of key milestones in BioAlliance Pharma’s clinical development program

Recurring revenue streams reflect the international deployment of Loramyc® BioAlliance Pharma SA (Euronext Paris –BIO), a company dedicated to specialty and orphan pharma products in oncology and supportive care, today reported a consolidated turnover of €604,000 for the first quarter of 2011. This turnover is constituted for €560,000 of recurring revenues from licensing agreements for Loramyc®. These revenues are similar…read more →

BioAlliance Pharma expands its Loramyc® franchise in Japan

with Sosei in a deal valued up to 18.5M$ BioAlliance Pharma SA (Euronext Paris –BIO), a company dedicated to specialty and orphan pharma products in oncology and supportive care, today announced that it has entered into an exclusive licensing agreement with Sosei Co. Ltd. (a wholly owned subsidiary of Sosei Group Corporation – TSE Mothers Index: 4565) for commercialization rights…read more →

BioAlliance Pharma accelerates its European clinical development of clonidine Lauriad™

The product becomes part of the Company’s Orphan Oncology Business Unit BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to specialty and orphan pharma products in oncology and supportive care, today announced the extension of its ongoing clonidine Lauriad™ phase II clinical trial in chemoradiation therapy induced oral mucositis in patients with head and neck cancer to Germany…read more →

Publication of the 2010 Annual Report

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, today announced that its 2010 Annual Report, in its capacity as Reference Document, was registered with the French Market Authorities on April 7, 2011. It is available free of charge to the public upon request as per current legal regulations at…read more →

Livatag® (Doxorubicin Transdrug™) follow up demonstrates significant survival increase in advanced hepatocellular carcinoma patients

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, today announced the update of its preliminary positive survival data with Livatag® (doxorubicin Transdrug™). Livatag® is a treatment presented in nanoparticles able to deliver doxorubicin in chemoresistant cells. Livatag® was granted an orphan drug status in Europe and in the United…read more →

BioAlliance Pharma receives €2 million in funding for peptide applications of the patented LauriadTM mucoadhesive technology

BioAlliance is capitalizing on its mucosal know-how BioAlliance Pharma SA (Euronext Paris-BIO), a company dedicated to the supportive care and treatment of cancer patients, today announced the award of €2 million in funding over 30 months from the « Fond Unique Interministériel » (a French program supporting collaborative research projects) including an amount of €743,000 specifically allocated to BioAlliance Pharma….read more →

BioAlliance Pharma appoints Judith Greciet Deputy Chief Operating Officer

Experienced pharma industry executive, Judith Greciet brings robust performance record to an Innovation Company BioAlliance Pharma SA (Euronext Paris-BIO), a company dedicated to the supportive care and treatment of cancer patients, today announced that it has strengthened its management team with the appointment of Judith Greciet as Deputy Chief Operating Officer, in charge of Operations and R&D. Judith Greciet joins…read more →

Consolidated turnover for 2010

Exceptional performance linked to international licensing agreements BioAlliance Pharma SA (Euronext Paris-BIO), a company dedicated to the supportive care and treatment of cancer patients, today announced a consolidated turnover for 2010 of €22.5 million – up from €7.5 million in 2009. This exceptional performance was due to the sales and licensing agreements implemented for Loramyc® (Oravig® in the United States)….read more →